Detail akcie Syndax Pharmaceut online

Business Summary: Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Syndax Pharmaceuticals Inc revenues increased from $16M to $103.9M. Net loss decreased 3% to $217.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Pharmaceuticals segment loss decrease of 13% to $210.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.63 to -$2.52.